Gene-Therapy Maker Sarepta Tanks After Patient Death

Gene-Therapy Maker Sarepta Tanks After Patient Death  The Wall Street JournalSarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.  MarketWatchTeenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies  STATSarepta Shares Fall on Report of Patient Death After Gene Therapy  BloombergPatient Dies After Receiving Sarepta’s Gene Therapy  Barron’s…
Read More